Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, that focuses on developing immuno-oncology products utilizing gene-edited T-cells expressing chimeric antigen receptors to target and eliminate cancer cells. The company operates in two segments: Therapeutics and Plants. Its lead product candidate, UCART19, is designed for treating CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia. Other notable product candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART123 for acute myeloid leukemia, and UCART22 for B-cell acute lymphoblastic leukemia. Additionally, Cellectis is working on UCARTCS1 and ALLO-715 for multiple myeloma. Beyond its therapeutic endeavors, the company also produces high oleic soybean oil and other soybean products. Cellectis has established strategic partnerships with several organizations, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center, to further its research and development efforts. Founded in 1999, Cellectis aims to innovate in the field of gene editing and cancer treatment.
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
Cyto Pulse Sciences
Acquisition in 2010
Cyto Pulse Sciences is a biomedical device and treatment development company. It develops electric field based devices for production of DNA therapeutic vaccines, delivery of DNA vaccines, modification of cell genomes to correct genetic defects, production of hybridoma cell vaccines by fusing immune system cells and tumor cells, and the production of hybridomas used to produce monoclonal antibodies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.